Last updated on July 2019

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

Brief description of study

The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures.

Detailed Study Description

Patients with treatment resistant depression who meet all inclusion criteria and do not meet any exclusion criteria will be randomized to either electroconvulsive therapy (ECT) three times per week or ketamine infusion two times per week. Patients will answer questionnaires about their symptoms prior to treatments. The acute treatment phase of the study will last three to five weeks. Depending on response to treatment, some patients will be followed for an additional six months.

Clinical Study Identifier: NCT03113968

Find a site near you

Start Over

Yale School of Medicine

New Haven, CT United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Mount Sinai

New York, NY United States
  Connect »